Report
Aelis Farma - Publication in 'Nature Medicine' highlights AEF0117's therapeutic potential for cannabis addiction
Aelis announced a publication in the prestigious journal ‘Nature Medicine' describing the pharmacological class of cannabinoid receptor 1 signaling-specific inhibitors (CB1-SSi) and revealing the clinical data detail of their lead candidate ‘AEF0117' for the treatment of cannabis use disorder (CUD)AEF0117 is currently undergoing additional clinical testing and recruitment for the ongoing Ph2b is expected to be completed in October TP and BUY rating unchanged; 12-month news flow includes readouts from the Ph1/2 in Down syndrome (by year-end) and Ph2b in CUD (mid '24)
Underlying
AELIS FARMA SA
Provider
Degroof Petercam
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
David Seynnaeve, PhD
Other Reports on these Companies
Other Reports from Degroof Petercam
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.